Latest Sales Guidance News

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Fenix Resources has achieved a record quarterly iron ore shipment of 1.2 million tonnes, driving a strong cash increase to A$79 million and reaffirming its FY26 production guidance.

Vita Life Sciences forecasts solid sales and profit growth for FY2025, driven by strong performances in Malaysia and Singapore, while cautiously managing challenges in China exports.

Atomos Limited has exercised 259.8 million options, raising $7.8 million to reduce its debt and boost confidence in hitting $23–25 million sales and positive EBITDA in the first half of 2026.

Ryman Healthcare reports a significant financial turnaround with its first positive free cash flow in over ten years, alongside upgraded sales and cost-saving targets for FY26 and completion of a major NZD 2 billion refinancing.

Ryman Healthcare has reported its first positive free cash flow in over a decade, driven by cost reductions and stronger sales momentum, while upgrading its sales guidance for FY26.

James Hardie Industries reports a 34% jump in Q2 FY26 net sales driven by the AZEK acquisition and European growth, while grappling with margin pressures and integration costs.

Atomos Limited has upgraded its FY26 earnings guidance, forecasting significant sales growth and a return to EBITDA profitability driven by strong demand and a revamped sales strategy.

Neuren Pharmaceuticals reported a milestone quarter with DAYBUE net sales reaching US$101.1 million, driving a 24% jump in royalty income. The expanding patient base and community physician uptake signal strong growth ahead.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

Image Resources has trimmed its heavy mineral concentrate sales guidance for 2025 by around 9%, citing weaker demand and logistical challenges, while extending repayment terms on prepayment facilities.